SCHEMBL31114767

SCHEMBL31114767

CC1(C)OB(c2ccc(F)cc2O)OC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 4/20 0.47
LIPG Q9Y5X9 4/20 0.47
CA9 Q16790 4/20 0.41
CA3 P07451 2/20 0.41
CA6 P23280 2/20 0.41
CA5A P35218 2/20 0.41
CA14 Q9ULX7 2/20 0.41
CA5B Q9Y2D0 2/20 0.41
CA1 P00915 4/20 0.39
CA2 P00918 4/20 0.39
PDE3A Q14432 1/20 0.39
CXCR2 P25025 4/20 0.38
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
CA12 O43570 1/20 0.32
CA4 P22748 1/20 0.32
CA7 P43166 1/20 0.32
JAK2 O60674 2/20 0.32
BTK Q06187 2/20 0.32
F11 P03951 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28961806 1.00 LPL (0.47) LPLLIPGCA9CA3CA6
SCHEMBL1095116 0.86 LPL (0.47) LPLLIPGCA9CA3CA6
SCHEMBL897058 0.81 LPL (0.50) LPLLIPGCA1CA2PDE3A
SCHEMBL5477046 0.81 LPL (0.35) LPLLIPGCA9CA3CA6
SCHEMBL29424567 0.81 LPL (0.50) LPLLIPGCA1CA2PDE3A
SCHEMBL31605738 0.80 LPL (0.49) LPLLIPGCA1CA2PDE3A
SCHEMBL6311907 0.80 LPL (0.49) LPLLIPGCA1CA2PDE3A
SCHEMBL15476117 0.80 TRPA1 (0.43) LPLLIPGCA9CA3CA6
SCHEMBL30571297 0.80 TRPA1 (0.43) LPLLIPGCA9CA3CA6
SCHEMBL17501095 0.79 LPL (0.47) LPLLIPGCA9CA3CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
US-20240391881-A1 PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE ORIGIANT PHARMACEUTICAL CO., LTD. (CN) 2024-11-28 US disclosed
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-10-31 US disclosed
WO-2024188994-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-09-19 WO disclosed
EP-4410787-A1 PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE Origiant Pharmaceutical Co., Ltd (CN) 2024-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES NLRP3, NOD1, NLRP1 LPL 3815/4885LIPG 4608/4885CA9 4481/4885
US-20240391881-A1 PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE NLRP3, NLRP1, NOD1 LPL 640/4885LIPG 2084/4885CA9 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.